Display options
Cite
Borg J, Campos A, Diema C, et al. Spectral counting assessment of protein dynamic range in cerebrospinal fluid following depletion with plasma-designed immunoaffinity columns. Clin Proteomics. 2011;8(1):6doi: 10.1186/1559-0275-8-6.
Borg, J., Campos, A., Diema, C., Omeñaca, N., de Oliveira, E., Guinovart, J., & Vilaseca, M. (2011). Spectral counting assessment of protein dynamic range in cerebrospinal fluid following depletion with plasma-designed immunoaffinity columns. Clinical proteomics, 8(1), 6. https://doi.org/10.1186/1559-0275-8-6
Borg, Jacques, et al. "Spectral counting assessment of protein dynamic range in cerebrospinal fluid following depletion with plasma-designed immunoaffinity columns." Clinical proteomics vol. 8,1 (2011): 6. doi: https://doi.org/10.1186/1559-0275-8-6
Borg J, Campos A, Diema C, Omeñaca N, de Oliveira E, Guinovart J, Vilaseca M. Spectral counting assessment of protein dynamic range in cerebrospinal fluid following depletion with plasma-designed immunoaffinity columns. Clin Proteomics. 2011 Jun 03;8(1):6. doi: 10.1186/1559-0275-8-6. PMID: 21906361; PMCID: PMC3167203.
Copy Download .nbib Format: NLM
Share it on

Clin Proteomics. 2011 Jun 03;8(1):6. doi: 10.1186/1559-0275-8-6.

Spectral counting assessment of protein dynamic range in cerebrospinal fluid following depletion with plasma-designed immunoaffinity columns.

Clinical proteomics

Jacques Borg, Alex Campos, Claudio Diema, Núria Omeñaca, Eliandre de Oliveira, Joan Guinovart, Marta Vilaseca

Affiliations

  1. Laboratoire de Neurobiochimie, Université Jean Monnet, Saint-Etienne, France. [email protected].

PMID: 21906361 PMCID: PMC3167203 DOI: 10.1186/1559-0275-8-6

Abstract

BACKGROUND: In cerebrospinal fluid (CSF), which is a rich source of biomarkers for neurological diseases, identification of biomarkers requires methods that allow reproducible detection of low abundance proteins. It is therefore crucial to decrease dynamic range and improve assessment of protein abundance.

RESULTS: We applied LC-MS/MS to compare the performance of two CSF enrichment techniques that immunodeplete either albumin alone (IgYHSA) or 14 high-abundance proteins (IgY14). In order to estimate dynamic range of proteins identified, we measured protein abundance with APEX spectral counting method.Both immunodepletion methods improved the number of low-abundance proteins detected (3-fold for IgYHSA, 4-fold for IgY14). The 10 most abundant proteins following immunodepletion accounted for 41% (IgY14) and 46% (IgYHSA) of CSF protein content, whereas they accounted for 64% in non-depleted samples, thus demonstrating significant enrichment of low-abundance proteins. Defined proteomics experiment metrics showed overall good reproducibility of the two immunodepletion methods and MS analysis. Moreover, offline peptide fractionation in IgYHSA sample allowed a 4-fold increase of proteins identified (520 vs. 131 without fractionation), without hindering reproducibility.

CONCLUSIONS: The novelty of this study was to show the advantages and drawbacks of these methods side-to-side. Taking into account the improved detection and potential loss of non-target proteins following extensive immunodepletion, it is concluded that both depletion methods combined with spectral counting may be of interest before further fractionation, when searching for CSF biomarkers. According to the reliable identification and quantitation obtained with APEX algorithm, it may be considered as a cheap and quick alternative to study sample proteomic content.

References

  1. Nat Protoc. 2008;3(9):1444-51 - PubMed
  2. Neurobiol Aging. 2005 Feb;26(2):207-27 - PubMed
  3. J Proteome Res. 2008 Jan;7(1):164-9 - PubMed
  4. Proteomics. 2007 Oct;7(19):3470-80 - PubMed
  5. Proteomics Clin Appl. 2010 Jul;4(6-7):613-7 - PubMed
  6. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):179-89 - PubMed
  7. Int Rev Neurobiol. 2006;73:29-98 - PubMed
  8. J Proteome Res. 2008 Jan;7(1):254-65 - PubMed
  9. J Proteome Res. 2007 Sep;6(9):3558-65 - PubMed
  10. J Proteome Res. 2005 Mar-Apr;4(2):410-6 - PubMed
  11. J Proteome Res. 2008 Jan;7(1):386-99 - PubMed
  12. J Proteome Res. 2008 Oct;7(10):4409-21 - PubMed
  13. Proteomics. 2007 Feb;7(3):469-73 - PubMed
  14. Proteomics Clin Appl. 2008 Mar;2(3):428-36 - PubMed
  15. J Alzheimers Dis. 2006 Aug;9(3):293-348 - PubMed
  16. PLoS One. 2010 Jun 11;5(6):e10980 - PubMed
  17. J Proteomics. 2009 Aug 20;72(6):945-51 - PubMed
  18. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1519-30 - PubMed
  19. Mol Cell Proteomics. 2006 Nov;5(11):2167-74 - PubMed
  20. J Proteome Res. 2007 Sep;6(9):3739-51 - PubMed
  21. Mol Cell Proteomics. 2010 May;9(5):1006-21 - PubMed
  22. Nat Biotechnol. 2007 Jan;25(1):117-24 - PubMed

Publication Types